Pharmacogenomic tests to predict clozapine response
Topic Status Incomplete
Pharmacogenomic tests to predict clozapine response in treatment-resistant schizophrenia
Specialities: Mental and behavioural disorders
Summary
Health Technology Wales researchers searched for evidence on the clinical and cost effectiveness of pharmacogenomic testing to predict clozapine response and clozapine-related adverse events in people with treatment-resistant schizophrenia.
A decision on whether to progress this topic to full appraisal is pending.
Topic Exploration Report
TER659 05.2026
Health Technology Wales Partners
